A two-year real-world study of Renalytix’s FDA-approved KidneyIntelX.dkd test showed improved kidney function and targeted treatment in 2,470 patients with type 2 diabetes.
Read More
Labcorp studies report new blood-based tools, including the Metabolic Vulnerability Index, may improve risk assessment for MASLD and MASH, offering enhanced prediction of adverse liver outcomes, according to recent peer-reviewed research.
Read More
Research suggests that only 12% of men receiving testosterone prescriptions underwent appropriate testing.
Read More
Updated criteria integrate clinical manifestations and genetic testing to reduce the time required to reach an informed diagnosis.
Read More
A multicenter clinical trial found the HelioLiver blood test detected early-stage liver cancer with 71.9% sensitivity, outperforming ultrasound’s 36.8%.
Read More